Skip to content
OpenCapital
Get started

Spyre Therapeutics, Inc. SYRE AFS and Trading Securities - Unrealized Loss Position Fair Value

AFS and Trading Securities - Unrealized Loss Position Fair Value at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——

Other financials

Income statement

See full
Revenue-—
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-—
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s afs and trading securities - unrealized loss position fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s AFS and trading securities - unrealized loss position fair value?
Spyre Therapeutics, Inc. (SYRE) reported AFS and trading securities - unrealized loss position fair value of $432M in Q1 2026.
How has Spyre Therapeutics, Inc.'s AFS and trading securities - unrealized loss position fair value changed year-over-year?
Spyre Therapeutics, Inc.'s AFS and trading securities - unrealized loss position fair value increased by 310.8% year-over-year, from $105.15M to $432M.
What is the long-term trend for Spyre Therapeutics, Inc.'s AFS and trading securities - unrealized loss position fair value?
Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s AFS and trading securities - unrealized loss position fair value has grown at a 93.0% compound annual growth rate (CAGR), from $25.17M to $180.96M.